Navigation Links
Does our DNA determine how well we respond to stem-cell transplantation?
Date:1/19/2011

SEATTLE Do genetic variations in DNA determine the outcome and success in patients who undergo stem-cell transplantation to treat blood cancers and predict complications? The National Heart, Blood and Lung Institute of the National Institutes of Health has awarded a $4.3 million, four-year grant to Fred Hutchinson Cancer Research Center to help find out.

John Hansen, M.D., a member of the Hutchinson Center's Clinical Research Division and medical director of Clinical Immunogenetics at Seattle Cancer Care Alliance, will lead the genome-wide association study of all patients who have been treated with an allogeneic hematopoietic cell transplant (HCT) at the Hutchinson Center between 1992 and 2010. Allogeneic stem-cell transplants involve infusing healthy stem cells from the blood or bone marrow of related and unrelated donors into the blood of patients whose blood-cell-producing bone marrow is diseased by leukemia and lymphoma, among other illnesses.

The new study will expand upon earlier research begun in 2006 and will increase the sample size three fold to 5,000 transplants, thus improving the power of identifying the genetic variants associated with HCT outcome.

Among the study's goals are to identify genetic variations among patients that could account for the risk and severity of acute and chronic graft-versus-host disease, organ toxicity, opportunistic infection, relapse and overall survival. Genetic variants associated with HCT outcome will be validated as markers for assessing risk prior to patients receiving transplants and to enhance counseling and treatment planning.

Researchers also will use the results to gain insights into disease processes responsible for treatment complications and the rationale for developing novel targeted therapies for preventing and controlling these complications.

Bone-marrow and stem-cell transplantation was developed at the Hutchinson Center as highly successful treatments for blood cancers and some autoimmune diseases. Researchers at the Hutchinson Center and its clinical partner, SCCA, have performed more transplants cumulatively over the years than any other center in the world. In 2010, about 60,000 people worldwide underwent bone- or stem-cell transplants, and by the end of 2011 it is expected that about 1 million people worldwide will have been treated by this life-saving therapy, which was pioneered by the Hutchinson Center's E. Donnall Thomas, M.D., who in 1990 received the Nobel Prize in physiology or medicine for this advance.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Mayo Clinic determines lifetime risk of adult rheumatoid arthritis
2. Jefferson study determines bone marrow stromal stem cells may aid in stroke recovery
3. MRI may help determine time of stroke onset
4. UT Southwestern study to determine whether leptin helps type 1 diabetes patients
5. For sufferers of an early-onset dementia, career choice may determine location of disease in brain
6. OHSU researchers able to determine brain maturity through analyzing MRI scans
7. Micro-RNA determines malignancy of lung cancer
8. Location determines social network influence, CCNY-led team finds
9. Can I buy you a drink? Genetics may determine sensitivity to other peoples drinking behavior
10. Delivery Method May Determine the Bacteria Babies Acquire
11. New possibility to determine the severity of appendicitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Brady ... announced that its B-595 and B-7569 vinyl label materials received ... and warning labels are tested to remain intact and legible, for use on chemical ...
(Date:4/21/2017)... Portland, Maine (PRWEB) , ... April 21, 2017 ... ... agency, today announced it’s been named Agency of Record (AOR) for Theravent, ... reduce or eliminate snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... exciting new partnership with the highly regarded and well renowned Asian distributor, Discovery ... myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and strengthen Airway’s ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a home care ... Utah (APCUT) and has appointed Rex Wheeler as its new Director of Business Development. ... agency and our ability to provide quality care to the community,” said Tammara Brown, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal mandate, fines, controversy, ... between the Obamacare program that most Republicans love to hate and Texas Agriculture ... kill hogs. , Like Obamacare, the Miller program centers upon a federal ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
Breaking Medicine Technology: